253 results on '"Jongen-Lavrencic, M"'
Search Results
2. Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome
3. Determinants of lenalidomide response with or without erythropoiesis-stimulating agents in myelodysplastic syndromes:the HOVON89 trial
4. Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine
5. Correction: Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS
6. Improved survival in adult patients with acute lymphoblastic leukemia in the Netherlands: a population-based study on treatment, trial participation and survival
7. Expression of a passenger miR-9* predicts favorable outcome in adults with acute myeloid leukemia less than 60 years of age
8. Aberrant expression of miR-9/9* in myeloid progenitors inhibits neutrophil differentiation by post-transcriptional regulation of ERG
9. Treatment, trial participation and survival in adult acute myeloid leukemia: a population-based study in the Netherlands, 1989–2012
10. P406: ENHANCED SIGNIFICANCE OF FLT3-ITD RESIDUAL DISEASE DETECTION ON TREATMENT OUTCOME IN ACUTE MYELOID LEUKEMIA
11. Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome.
12. Comparative therapeutic value of post-remission approaches in patients with acute myeloid leukemia aged 40–60 years
13. Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS
14. Population-based analyses among 184 patients diagnosed with large granular lymphocyte leukemia in the Netherlands between 2001 and 2013
15. Effectiveness of azacitidine for the treatment of higher-risk myelodysplastic syndromes in daily practice: results from the Dutch population-based PHAROS MDS registry
16. The prognostic relevance of miR-212 expression with survival in cytogenetically and molecularly heterogeneous AML
17. Inferior outcome of addition of the aminopeptidase inhibitor tosedostat to standard intensive treatment for elderly patients with aml and high risk mds
18. 823O Preliminary pharmacokinetics (PK) and pharmacodynamic (PD) analysis of the CD123 NK cell engager (NKCE) SAR443579 in patients (pts) with relapsed or refractory acute myeloid leukemia (R/R AML), B cell acute lymphoblastic leukemia (B-ALL) or high risk-myelodysplasia (HR-MDS)
19. Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial
20. MicroRNA signatures characterize multiple myeloma patients
21. The long non-coding RNA Cancer Susceptibility 15 (CASC15) is induced by isocitrate dehydrogenase (IDH) mutations and maintains an immature phenotype in adult acute myeloid leukemia
22. Standardised immunophenotypic analysis of myeloperoxidase in acute leukaemia
23. Panobinostat and decitabine prior to donor lymphocyte infusion in allogeneic stem cell transplantation
24. Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDS
25. Correction: Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS
26. Effectiveness of azacitidine in higher-risk myelodysplastic syndromes
27. BCR/ABL-mediated downregulation of genes implicated in cell adhesion and motility leads to impaired migration toward CCR7 ligands CCL19 and CCL21 in primary BCR/ABL-positive cells
28. Recombinant human erythropoietin improves health-related quality of life in patients with rheumatoid arthritis and anaemia of chronic disease; utility measures correlate strongly with disease activity measures
29. 17p13/TP53 deletion in B-CLL patients is associated with microRNA-34a downregulation
30. Effect of l-NAME, an inhibitor of nitric oxide synthesis, on plasma levels of IL-6, IL-8, TNFα and nitrite/nitrate in human septic shock
31. miRNA analysis in B-cell chronic lymphocytic leukaemia: proliferation centres characterized by low miR-150 and high BIC/miR-155 expression#
32. Interaction of inflammatory cytokines and erythropoeitin in iron metabolism and erythropoiesis in anaemia of chronic disease
33. Richtlijn Acute promyelocytenleukemie (APL): richtlijnen voor diagnostiek en behandeling
34. Phase-II trial with M-CAVe-CEC as a salvage chemotherapeutic regimen for early relapsed or primary refractory Hodgkin's disease
35. R-h-erythropoietin counteracts the inhibition of in vitro erythropoiesis by tumour necrosis factor alpha in patients with rheumatoid arthritis
36. Effects of isolated limb perfusion with tumour necrosis factor-alpha on the function of monocytes and T lymphocytes in patients with cancer
37. Effect of recombinant human erythropoietin on anaemia and disease activity in patients with rheumatoid arthritis and anaemia of chronic disease: a randomised placebo controlled double blind 52 weeks clinical trial
38. Course and characteristics of anaemia in patients with rheumatoid arthritis of recent onset
39. IL-6-induced anaemia in rats: possible pathogenetic implications for anaemia observed in chronic inflammations
40. CD123 expression levels in 846 acute leukemia patients based on standardized immunophenotyping
41. The versatile nature of miR-9/9* in human cancer
42. GRAFT VERSUS LEUKEMIA EFFECT OF ALLOGENEIC STEM CELL TRANSPLANTATION AND MINIMAL RESIDUAL DISEASE IN PATIENTS WITH AML IN FIRST COMPLETE REMISSION
43. Ciprofloxacin-Induced Toxic Epidermal Necrolysis in a Patient with Systemic Lupus Erythematosus
44. Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML
45. Circular RNAs of the nucleophosmin (NPM1) gene in acute myeloid leukemia
46. The non-coding RNA landscape of human hematopoiesis and leukemia
47. Classification of pediatric acute myeloid leukemia based on miRNA expression profiles
48. The non-coding RNA landscape of human hematopoiesis and leukemia
49. Het myelodysplastisch syndroom in Nederland: een population-based onderzoek naar incidentie, primaire behandeling en overleving in de periode 2001-2010
50. Treatment, trial participation and survival in adult acute myeloid leukemia: a population-based study in the Netherlands, 1989-2012
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.